Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 6Other hematologic neoplasm 4CNS 4Thoracic 3Sarcoma 3Gastrointestinal 2Breast 2Plasma cell 1Other neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Endocrine 1Classical hematology 1

Conditions

Thrombocytopenia 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Cyclophosphamide 229fludarabine phosphate 206fludarabine 163Busulfan 150Mycophenolic Acid 135Tacrolimus 133Whole-Body Irradiation 132Peripheral Blood Stem Cell Transplantation 121Cytarabine 101Azacitidine 100Antilymphocyte Serum 98Melphalan 96Cyclosporine 96Methotrexate 87Imatinib Mesylate 87Filgrastim 85Decitabine 66Granulocyte Colony-Stimulating Factor 60Thiotepa 57venetoclax 53Stem Cell Transplantation 53thymoglobulin 51Radiotherapy 49Cord Blood Stem Cell Transplantation 42nilotinib 40Clofarabine 38Dasatinib 37Methylprednisolone 36ruxolitinib 35Etoposide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × DNA Methylation × Myeloid × Clear all
NCT01165996 2019-03-04

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Case Comprehensive Cancer Center

Phase 1/2 Completed
25 enrolled 13 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Thrombocytopenia, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡